Regorafenib Doubles 12-Month Survival Compared with Lomustine in Recurrent GBM
This drug looks good in a small study (you can not always rely on small studies) - doubling survival percentage at 12 months. The drug is approved for other types of cancers so it is available off label. Insurance companies might complain. I do not know the cost but my guess is that it is expensive. If anyone is going to try it, please join the virtual trial (virtualtrials.com) first so we can quickly find out how it is working. We might also be able to help you fight your insurance company if they deny it.
This article also points out that you can have a huge benefit without moving the median progression free survival. This issue has come up in a few other clinical trials recently. The median survival or progression free survival is not increased so they think the drug failed. However, the median doesn't take into account the long survival tails of these trials. The recent article about PVSRIPO demonstrated this. A huge benefit at 2,3 and 4 years, but the median doesn't change much.
Posted on: 01/23/2019
Click HERE to return to brain tumor news headlines